European Biomanufacturing SPAC Launched, Backed By Former Sanofi-Aventis CEO Le Fur

With €150m Capital Raise Announced

EureKING hopes to help develop and manufacture novel cell and gene therapies and live biotherapeutics, among other types of biologics, through a number of strategic acquisitions.    

EureKING Will Help Firms Manufacture Novel Biotherapeutics • Source: Shutterstock

The first European special-purpose acquisition company (SPAC) in the healthcare industry dedicated to bioproduction was launched today and hopes to become a leading CDMO in the region.

The new firm, EureKING, has announced a €150m ($158m) capital raise with an eye to investing in and buying companies...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

More from Scrip

Chinese Biotechs Sweep ADC Plus PD-(L)1/VEGF Bispecific Combos Into Phase II

 

Chinese firms Junshi, Minghui and RemeGen rank among the world’s few players progressing antibody-drug conjugates combined with PD-(L)1/VEGF bispecific antibodies in Phase II trials for various cancers.

Sarepta Voluntarily Stops Shipments Of Elevidys After Previously Refusing FDA Request

 
• By 

The company had planned to keep its DMD gene therapy available for ambulatory patients, but now says pausing shipments may enable a better working relationship with the US FDA while safety labeling is updated.

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: J&J delivers in Q2 despite Stelara drop; Sarepta cuts jobs as Elevidys slumps; AI is inevitable but needs to be applied appropriately; China’s mid-cap companies thrive; and a look behind Glenmark’s landmark trispecific deal.